Induction of the Chlamydia Muridarum Stress/persistence Response Increases Azithromycin Treatment Failure in a Murine Model of Infection

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2013 Dec 18

PMID 24342653

Citations 20

Authors

R Phillips-Campbell

J Kintner

R V Schoborg

Affiliations

Soon will be listed here.

Abstract

Viable but noninfectious (stressed/persistent) chlamydiae are more resistant to azithromycin (AZM) in culture than are organisms in the normal developmental cycle. Chlamydia muridarum-infected mice were exposed to amoxicillin to induce the organisms to enter the persistent/stressed state and subsequently treated with AZM. AZM treatment failure was observed in 22% of persistently infected mice, with an average of 321,667 inclusion-forming units (IFU) shed after AZM treatment. Productively infected mice had a 9% rate of AZM treatment failure and shed an average of 12,083 IFU. These data suggest that stressed chlamydiaeare more resistant to frontline antichlamydial drugs in vivo.

Citing Articles

Assessment of Antimicrobial Therapy in Eradicating Chlamydia muridarum in Research Mice: Immune Status and Its Impact on Outcomes.

Palillo M, Carrasco S, Mishkin N, Palillo J, Lynch D, Lawton S J Am Assoc Lab Anim Sci. 2025; 64(1):76-88.

PMID: 40035285 PMC: 11808367. DOI: 10.30802/AALAS-JAALAS-24-069.

Antimicrobial Resistance in Curable Sexually Transmitted Infections.

Giacani L, Bradshaw C, Muzny C, Graves K, Pasricha S, Jordan S Curr HIV/AIDS Rep. 2025; 22(1):14.

PMID: 39856345 DOI: 10.1007/s11904-025-00722-7.

The MraY Inhibitor Muraymycin D2 and Its Derivatives Induce Enlarged Cells in Obligate Intracellular and and Break the Persistence Phenotype in .

Lockener I, Behrmann L, Reuter J, Schiefer A, Klockner A, Krannich S Antibiotics (Basel). 2024; 13(5).

PMID: 38786149 PMC: 11117252. DOI: 10.3390/antibiotics13050421.

Aberrant Bodies: An Alternative Metabolic Homeostasis Allowing Survivability?.

Kozusnik T, Adams S, Greub G Microorganisms. 2024; 12(3).

PMID: 38543546 PMC: 10972484. DOI: 10.3390/microorganisms12030495.

The Effect of Amoxicillin Pre-Exposure on Treatment Outcomes and Antimicrobial Susceptibility in Patients with Urogenital Infection.

You C, Liao M, Wang M, Zhao L, Li L, Ye X Infect Drug Resist. 2023; 16:3575-3587.

PMID: 37305735 PMC: 10257477. DOI: 10.2147/IDR.S410410.

References

Sena A, Lensing S, Rompalo A, Taylor S, Martin D, Lopez L . Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy. J Infect Dis. 2012; 206(3):357-65. PMC: 3490700. DOI: 10.1093/infdis/jis356. View

Matsumoto A, Manire G . Electron microscopic observations on the effects of penicillin on the morphology of Chlamydia psittaci. J Bacteriol. 1970; 101(1):278-85. PMC: 250478. DOI: 10.1128/jb.101.1.278-285.1970. View

Beale A, Upshon P . Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid, or azithromycin. Antimicrob Agents Chemother. 1994; 38(9):1937-43. PMC: 284665. DOI: 10.1128/AAC.38.9.1937. View

Rank R, Whittimore J, Bowlin A, Wyrick P . In vivo ultrastructural analysis of the intimate relationship between polymorphonuclear leukocytes and the chlamydial developmental cycle. Infect Immun. 2011; 79(8):3291-301. PMC: 3147583. DOI: 10.1128/IAI.00200-11. View

Sternak S, Skerk V . [Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice]. Med Glas (Zenica). 2010; 7(1):26-31. View

Wyrick P, Knight S . Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin. J Antimicrob Chemother. 2004; 54(1):79-85. DOI: 10.1093/jac/dkh283. View

Bragina E, Gomberg M, Dmitriev G . Electron microscopic evidence of persistent chlamydial infection following treatment. J Eur Acad Dermatol Venereol. 2002; 15(5):405-9. DOI: 10.1046/j.1468-3083.2001.00342.x. View

Cotter T, Miranpuri G, Ramsey K, Poulsen C, Byrne G . Reactivation of chlamydial genital tract infection in mice. Infect Immun. 1997; 65(6):2067-73. PMC: 175285. DOI: 10.1128/iai.65.6.2067-2073.1997. View

Phillips Campbell R, Kintner J, Whittimore J, Schoborg R . Chlamydia muridarum enters a viable but non-infectious state in amoxicillin-treated BALB/c mice. Microbes Infect. 2012; 14(13):1177-85. PMC: 3654801. DOI: 10.1016/j.micinf.2012.07.017. View

10.

Dean D, Suchland R, Stamm W . Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J Infect Dis. 2000; 182(3):909-16. DOI: 10.1086/315778. View

11.

Ramsey K, Miranpuri G, Sigar I, Ouellette S, Byrne G . Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome. Infect Immun. 2001; 69(8):5131-7. PMC: 98609. DOI: 10.1128/IAI.69.8.5131-5137.2001. View

12.

Kutlin A, Roblin P, Hammerschlag M . In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother. 1999; 43(9):2268-72. PMC: 89459. DOI: 10.1128/AAC.43.9.2268. View

13.

Horner P . The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection. Sex Transm Infect. 2006; 82(4):340-3. PMC: 2564728. DOI: 10.1136/sti.2005.019158. View

14.

Byrne G, Lehmann L, Landry G . Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun. 1986; 53(2):347-51. PMC: 260881. DOI: 10.1128/iai.53.2.347-351.1986. View

15.

Pitt R, Alexander S, Horner P, Ison C . Presentation of clinically suspected persistent chlamydial infection: a case series. Int J STD AIDS. 2013; 24(6):469-75. DOI: 10.1177/0956462412472815. View

16.

Reveneau N, Crane D, Fischer E, Caldwell H . Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. Antimicrob Agents Chemother. 2005; 49(5):1787-93. PMC: 1087634. DOI: 10.1128/AAC.49.5.1787-1793.2005. View

17.

Wang S, Papp J, Stamm W, Peeling R, Martin D, Holmes K . Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis. 2005; 191(6):917-23. DOI: 10.1086/428290. View